A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

NCT01223222 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Gram-positive, Skin Infections
Mild Eczema/Dermatoses
Atopic Dermatitis

Interventions

DRUG: LTX-109

Sponsor

Lytix Biopharma AS